Evidence map›Paper›PMID 39209825›Full record

ArticleNature communications2024

Adipocyte deletion of the oxygen-sensor PHD2 sustains elevated energy expenditure at thermoneutrality.

Rongling Wang, Mario Gomez Salazar, Iris Pruñonosa Cervera, Amanda Coutts, Karen French, Marlene Magalhaes Pinto, Sabrina Gohlke, Ruben García-Martín, Matthias Blüher, Christopher J Schofield and 12 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Belzutifan for HIF2A-Related Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Rongling WangCentre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-8719-938X
Mario Gomez SalazarCentre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Iris Pruñonosa CerveraCentre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Amanda CouttsDepartment of Biosciences, School of Science and Technology, Nottingham Trent University, Clifton, Nottingham, UK.ORCID 0000-0002-5005-1864
Karen FrenchCentre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Marlene Magalhaes PintoCentre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Sabrina GohlkeDepartment of Adipocyte Development and Nutrition, German Institute of Human Nutrition, Potsdam-Rehbrücke, Nuthetal, Germany.
Ruben García-MartínDepartment of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC (CNB-CSIC), Campus-UAM, Madrid, Spain.ORCID 0000-0003-2049-4960
Matthias BlüherHelmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany.ORCID 0000-0003-0208-2065
Christopher J SchofieldChemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research University of Oxford, Oxford, UK.ORCID 0000-0002-0290-6565
Ioannis KourtzelisHull York Medical School, York Biomedical Research Institute, University of York, York, UK.ORCID 0000-0003-3006-8885
Roland H StimsonCentre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-9002-6188
Cécile BénézechCentre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Mark ChristianDepartment of Biosciences, School of Science and Technology, Nottingham Trent University, Clifton, Nottingham, UK.ORCID 0000-0002-1616-4179
Tim J SchulzDepartment of Adipocyte Development and Nutrition, German Institute of Human Nutrition, Potsdam-Rehbrücke, Nuthetal, Germany.ORCID 0000-0002-8413-3972
Elias F GudmundssonIcelandic Heart Association, Kopavogur, Iceland.ORCID 0000-0002-7661-4872
Lori L JenningsNovartis Institutes for Biomedical Research, Cambridge, MA, USA.ORCID 0000-0001-5130-8417
Vilmundur G GudnasonIcelandic Heart Association, Kopavogur, Iceland.ORCID 0000-0001-5696-0084
Triantafyllos ChavakisCentre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-1869-5141
Nicholas M MortonCentre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Valur EmilssonIcelandic Heart Association, Kopavogur, Iceland.ORCID 0000-0001-9982-0524
Zoi MichailidouCentre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK. zoi.michailidou@ntu.ac.uk.ORCID 0000-0003-0085-4842

Funding

Wellcome Trust
6 · The paper itself

Abstract

Enhancing thermogenic brown adipose tissue (BAT) function is a promising therapeutic strategy for metabolic disease. However, predominantly thermoneutral modern human living conditions deactivate BAT. We demonstrate that selective adipocyte deficiency of the oxygen-sensor HIF-prolyl hydroxylase (PHD2) gene overcomes BAT dormancy at thermoneutrality. Adipocyte-PHD2-deficient mice maintain higher energy expenditure having greater BAT thermogenic capacity. In human and murine adipocytes, a PHD inhibitor increases Ucp1 levels. In murine brown adipocytes, antagonising the major PHD2 target, hypoxia-inducible factor-(HIF)-2a abolishes Ucp1 that cannot be rescued by PHD inhibition. Mechanistically, PHD2 deficiency leads to HIF2 stabilisation and binding of HIF2 to the Ucp1 promoter, thus enhancing its expression in brown adipocytes. Serum proteomics analysis of 5457 participants in the deeply phenotyped Age, Gene and Environment Study reveal that serum PHD2 associates with increased risk of metabolic disease. Here we show that adipose-PHD2-inhibition is a therapeutic strategy for metabolic disease and identify serum PHD2 as a disease biomarker.

Indexed as

Adipose Tissue, BrownEnergy MetabolismHypoxia-Inducible Factor-Proline DioxygenasesThermogenesisUncoupling Protein 1AdipocytesAdipocytes, BrownAdultAnimalsBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1FemaleHumansMaleMiceMice, Inbred C57BLBasic Helix-Loop-Helix ProteinsEGLN1 protein, humanEgln1 protein, mouseEndothelial PAS Domain-Containing Protein 1Hypoxia-Inducible Factor-Proline DioxygenasesOxygenUCP1 protein, humanUcp1 protein, mouseUncoupling Protein 1

Identifiers

PMID39209825
PMCPMC11362468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.